A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Hoffmann-La Roche

Overview

This observational disease registry is a prospective, national, non-interventional study designed to enroll participants who have received an initial diagnosis of unresectable, locally advanced (LA) or metastatic breast cancer (mBC), up to 6 months prior to registry enrolment. These participants will be prospectively followed for at least 5 years after study enrolment to evaluate their anti-cancer treatments. Data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.

Study Type

OBSERVATIONAL

Conditions

Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

Interventions

No interventionOTHER

No intervention was administered in this study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrolment, although they can have received anti-cancer treatment during that time Exclusion Criteria: There are no exclusion criteria for entry into this study.

Outcomes

Primary Outcomes

Progression-Free Survival (PFS) For Each Anti-Cancer Treatment Regimen

Time frame: Up to approximately 8 years

Secondary Outcomes

Overall Survival (OS)

Time frame: Up to approximately 8 years

Objective Response Rate (ORR) For Each Anti-Cancer Treatment Regimen

Time frame: Up to approximately 8 years

Number and Percentage of Participants Receiving Each Unique Treatment Regimen Overall and as First-Line Therapy Versus Second-Line Therapy Versus Subsequent-Line Therapy

Time frame: Up to approximately 8 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.